Nurtec ODT Generic: When Will Generic Rimegepant Be Available?
This page is aggregated from FDA records, court filings and company announcements. Coded and designed by Dr. Brian Staiger, PharmD, BCPS
Updated October 9, 2026 How we build our data
Nurtec ODT Generic at a Glance
Four quick answers from FDA records and our estimate.
- When is the first generic expected? March 2039 About 12.5 years away Why then?
- Has the FDA approved a generic? Not yet None in the FDA’s records yet Why not yet?
- When does the last patent end? March 2039 3 patents listed with the FDA
- Can you buy a generic today? Not yet No company lists one for sale
Generic rimegepant sulfate is expected to be available in March 2039, about 12.5 years away. None is for sale yet.
Why March 2039?
It is when Nurtec ODT’s patent 11,083,724 ends. That patent covers the product’s formulation and a way of using it, and once it ends, generics can go on sale as soon as the FDA approves them. We rate it probable: more likely than not, but it can still move.
Why hasn’t the FDA approved a generic yet?
That is normal before a launch. The FDA usually can’t give a generic its final approval while a patent or exclusivity still blocks it, so final approval often comes close to the day the generic can be sold. No company holds a “tentative” approval yet either (the FDA’s word for a generic that is ready but still blocked).
Will the generic cost less?
Usually, and more so as more companies sell one. 7 companies have applied to the FDA to make it. In the FDA’s study of past launches, pharmacies paid over 95% less once six or more companies sold a generic, which would take the $128.67 pharmacies pay per tablet for Nurtec ODT today to under $6.43. See the price estimate
What should I do now?
Keep taking Nurtec ODT as prescribed. When a generic arrives, your pharmacy may switch you to it automatically, and it may look different. What a generic means for you
Our month is only an estimate based on available information, so we never name a day.
Nurtec ODT by the Numbers
- Reason
- Patent expiresA patent that protects the brand runs out. After that, approved generics can be sold.
- How sure
- Probable More likely than not, but it can still move.
- Price competition
- Very strong 7 companies have filed, 7 first in line
- Brand sales
- $5.3B a yearBlockbuster
- FDA approved 2020 February 2020 FDA Orange Book
- Patents listed 3 last runs to March 2039 FDA Orange Book
- Pharmacies pay $128.67 per tablet, up 7.6% in a year NADAC, October 2026
- Medicare Part D spent $834.4M in 2025, for 127.8K people CMS Part D Spending by Drug
- Medicaid prescriptions 493K in the last four reported quarters, $624.8M CMS Medicaid drug utilization, to Q4 2025
Nurtec ODT’s Road to a Generic
Nurtec ODT has had the market to itself since the FDA approved it in February 2020 (Pfizer Inc). Its 3 listed patents run to March 2039. Generic companies have challenged its patents with the FDA since February 2024.
The first generic of Nurtec ODT is expected in March 2039.
Why that month: patent 11,083,724, on the product’s formulation and a way of using it, ends then.
Each bar runs from the brand’s approval to the day that protection ends. The green band is our projection for the first generic: a month, never a day, because legal dates move and a generic reaches shelves days to weeks after it is allowed. Sources: FDA Orange Book; the expected month from court records and company announcements.
Nurtec ODT Patents and FDA Protections
Every patent and exclusivity the FDA Orange Book lists for Nurtec ODT’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.
The one that matters for a generic launch: patent 11,083,724, which ends in March 2039, the month the first generic is expected.
| Patent | What it covers | Protects until | Status |
|---|---|---|---|
| 8,759,372 | The active ingredient; the product’s formulation | February 2033 | Active |
| 8,314,117 | The active ingredient; the product’s formulation; a way of using it (U-2718, U-3142) | February 2034 | Active |
| 11,083,724 Sets the expected month of generic availability | The product’s formulation; a way of using it (U-2718, U-3142) | March 2039 | Active |
Source: FDA Orange Book, application 212728. Patent numbers open the patent on Google Patents.
Patent Challenges to Nurtec ODT
The first patent challenge to Nurtec ODT reached the FDA in February 2024, from 7 companies on that first day. The FDA has not approved a first challenger’s generic yet.
What Is a Patent Challenge?
A generic company that wants to sell its version before Nurtec ODT’s patents run out can tell the FDA that a patent is invalid, or that its version does not infringe it. The FDA calls this a “Paragraph IV certification.” The brand company usually sues, and the FDA then generally cannot approve that generic for up to 30 months while the case runs. To reward going first, the companies that challenge first can get a 180-day head start: the FDA cannot approve the generics that came after them until it ends.
| Product | First challenged | Companies that day | 180-day head start | First challenger’s generic | Challenged patents run to | |
|---|---|---|---|---|---|---|
| Approved | On sale | |||||
| Orally disintegrating tablets, 75 mg | February 2024 | 7 companies | No decision yet | Not yet | Not yet | March 2039 |
Source: the FDA’s Paragraph IV Patent Certifications list, as of September 2026. The FDA began posting the 180-day decisions and the first challenger’s approval and first sale in June 2019: an older entry it has not updated since reads “Not posted”, and “Not yet” means the list records no such event. “Companies that day” is the FDA’s count of challenges that arrived on the first day.
Who Is Lined Up to Make Generic Rimegepant Sulfate
Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it.
Applied to the FDA
7 companies have applied to the FDA to make generic rimegepant sulfate.
The FDA names a company only once it approves its application, even tentatively, and it has not done that for these yet, so the companies are not named here. Names often come out in the brand company’s patent lawsuits or in the companies’ own announcements.
First in line. 7 of them were first in line, all filing on the first day any company did: they can share 180 days on the market before the other generics, which is why being first matters.
Generic companies have challenged Nurtec ODT’s patents with the FDA since February 2024: see the patent challenges.
Approved by the FDA
Not yet. The FDA has not approved a generic rimegepant sulfate. Final approval often comes close to the day a generic can be sold.
For Sale in Pharmacies
Not yet. No company lists a generic rimegepant sulfate for sale with the FDA.
Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what is for sale from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).
Nurtec ODT Price: What Pharmacies Pay and What Generics Usually Do
What Pharmacies Pay for Nurtec ODT 75 mg tablet
$128.67 per tablet in October 2026, up 7.6% from a year earlier.
Hover over or tap anywhere on the chart to see that month’s price.
See the numbers
| Month | Pharmacies paid per tablet |
|---|---|
| October 2026 | $128.67 |
| September 2026 | $128.67 |
| August 2026 | $128.66 |
| July 2026 | $128.68 |
| June 2026 | $128.71 |
| May 2026 | $128.70 |
| April 2026 | $128.75 |
| March 2026 | $128.75 |
| February 2026 | $128.75 |
| January 2026 | $128.75 |
| February 2024 | $119.63 |
| January 2024 | $119.63 |
NADAC: the national average price retail pharmacies pay to buy the medicine (CMS survey, updated weekly), the last price of each month for one package. It is not what you pay: that depends on your insurance or discount card.
What a Generic Could Cost
How we estimate it. We start from what pharmacies pay for Nurtec ODT today: $128.67 per tablet for Nurtec ODT 75 mg tablet in October 2026, from the national NADAC survey. Then we apply the FDA’s finding of how far that price usually falls as generic companies join: about 31% with one company, 44% with two, 73% with four and over 95% with six or more (the typical drop for every drug whose first generic came out from 2015 to 2017). Nurtec ODT has 7 companies lined up, so our estimate uses the figure for six or more companies. More companies would bring the price lower; fewer, less of a drop.
Dollar figures apply FDA’s median drops to the $128.67 pharmacies pay per tablet today. An estimate from the pattern, not a price quote: what you pay depends on your insurance or discount card.
Median prices pharmacies paid for the generic (invoice prices), compared with the brand’s price before generic entry, from FDA’s 2019 analysis “Generic Competition and Drug Prices”. At the manufacturer’s price FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker. A typical pattern, not a price quote for this medicine.
What Medicare and Medicaid Spend on Nurtec ODT
Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. Figures are before manufacturer rebates, which are confidential.
Medicare Part D Spending
What Medicare drug plans spent on Nurtec ODT, before manufacturer rebates.
- $214.8M
- January to March 2026, the latest CMS has posted
For 73,776 people, about $1,576 per prescription fill - $834.4M
- 2025, the whole year
For 127,821 people, about $1,521 per prescription fill
See the numbers
| Period | Spending | People | Per fill |
|---|---|---|---|
| January to March 2026 | $214,841,434 | 73,776 | $1,576.07 |
| 2025 | $834,434,733 | 127,821 | $1,520.97 |
Source: CMS Medicare Part D Spending by Drug, matched by the brand name Nurtec ODT only, so no generic is counted in it. What CMS says it is used for: This medication is used to prevent or treat migraine. Rimegepant may work by changing the amount of a certain natural substance in the brain.
Medicaid Prescriptions by Quarter
492,967 prescriptions in the four quarters to Q4 2025, $624.8M paid.
See the numbers
| Quarter | Prescriptions | Medicaid paid |
|---|---|---|
| Q4 2025 | 124,045 | $158,755,465 |
| Q3 2025 | 130,289 | $164,796,583 |
| Q2 2025 | 120,689 | $153,129,123 |
| Q1 2025 | 117,944 | $148,127,736 |
Source: CMS Medicaid State Drug Utilization Data, over Nurtec ODT’s own package codes.
Nurtec ODT Strengths and Forms
| Strength | Form | How it is taken | Approved | Status |
|---|---|---|---|---|
| EQ 75MG BASE | Tablet, orally disintegrating | Oral | February 2020 | Prescription reference product |
Source: FDA Orange Book, Pfizer Inc. Listed for sale today by Biohaven Pharmaceuticals, Inc, Pfizer Laboratories Div Pfizer Inc and Sportpharm LLC (FDA NDC Directory).
Nurtec ODT NDC Codes and Packages
Each Nurtec ODT package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.
| NDC | Product | Package | Company |
|---|---|---|---|
| 72618-3000-02 | RIMEGEPANT SULFATE 75 mg/1 tablet, orally disintegrating | blister pack of 8 tablets | Pfizer Laboratories Div Pfizer Inc |
| 72618-3000-02 | RIMEGEPANT SULFATE 75 mg/1 tablet, orally disintegrating | blister pack of 8 tablets | Pfizer Laboratories Div Pfizer Inc |
| 72618-3001-02 | RIMEGEPANT SULFATE 75 mg/1 tablet, orally disintegrating | carton of 4 dose packs of 1 blister pack of 2 tablets | Pfizer Laboratories Div Pfizer Inc |
| 72618-3001-02 | RIMEGEPANT SULFATE 75 mg/1 tablet, orally disintegrating | carton of 4 dose packs of 1 blister pack of 2 tablets | Pfizer Laboratories Div Pfizer Inc |
| 72618-3001-04 | RIMEGEPANT SULFATE 75 mg/1 tablet, orally disintegrating | blister pack of 2 tablets | Pfizer Laboratories Div Pfizer Inc |
| 85766-0096-08 | RIMEGEPANT SULFATE 75 mg/1 tablet, orally disintegrating | blister pack of 8 tablets | Sportpharm LLC |
Source: the FDA NDC Directory, current listings only. Only packages sold under Nurtec ODT’s own FDA approval (NDA 212728) are listed, never a generic. Some codes belong to companies that repackage Nurtec ODT: it is the same medicine in a different package.
What a Generic Nurtec ODT Means for You
Nothing Changes Until It Is in Pharmacies
Until a generic is actually for sale, keep filling Nurtec ODT as usual. When one arrives, there is nothing you need to sign up for.
Your Pharmacy May Switch You Automatically
Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.
It Will Probably Look Different
US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.
Your Insurance May Change Too
Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.
Until a generic is on US pharmacy shelves, be careful with websites that offer “generic Nurtec ODT”. The FDA warns that unlicensed online pharmacies sell counterfeit and unapproved medicines; its BeSafeRx page shows how to check a pharmacy.
Questions people ask about Nurtec ODT
Is there a generic for Nurtec ODT right now?
No. As of October 9, 2026 no generic rimegepant sulfate is listed for sale in the FDA NDC Directory.
When will Nurtec ODT go generic?
March 2039 is the expected month, and that is probable but not certain. It is when Nurtec ODT’s patent 11,083,724 ends. That patent covers the product’s formulation and a way of using it, and once it ends, generics can go on sale as soon as the FDA approves them.
Will generic rimegepant sulfate be the same as Nurtec ODT?
Yes in the ways that matter: the same active ingredient, strength and form, with proof that it reaches your blood the same way. Inactive ingredients can differ, which is why some people notice a different look or taste.
How much will the generic cost?
Nobody can say for sure before launch. 7 companies have applied to the FDA to make it. In the FDA’s study of past launches, pharmacies paid over 95% less once six or more companies sold a generic, which would take the $128.67 pharmacies pay per tablet for Nurtec ODT today to under $6.43. That is a pattern from past launches, not a prediction for this one.
Has the FDA approved a generic Nurtec ODT?
Not yet. The FDA Orange Book lists no approved generic version of Nurtec ODT.
When does the Nurtec ODT patent expire?
The FDA Orange Book lists 3 patents for Nurtec ODT; the last runs to March 2039. The one behind the expected month is patent 11,083,724, which ends in March 2039. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected month on this page (March 2039) weighs all of that.
Has anyone challenged the Nurtec ODT patents?
Yes. The first patent challenge to Nurtec ODT reached the FDA in February 2024, from 7 companies on that first day. The FDA has not approved a first challenger’s generic yet. A patent challenge (a “Paragraph IV certification”) is a generic company telling the FDA that a patent listed for the brand is invalid or will not be infringed by its version. The first companies to file one can earn a 180-day head start, during which the FDA cannot approve the generics that filed after them.
How much does Nurtec ODT cost now?
Pharmacies paid about $128.67 per tablet for Nurtec ODT 75 mg tablet in October 2026, by the national survey of what pharmacies pay (NADAC). That is the pharmacy’s cost, not your price: what you pay depends on your insurance or discount card.
Changes to This Projection
- First generic expected March 2039 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.
Every change to the expected month is logged here with the month we saw it.
Also Going Generic
- Bydureon BCiseExenatide SyntheticApril 2031
- TosymraSumatriptanJuly 2031
- LodocoColchicineNovember 2033
- FotivdaTivozanib Hydrochloride2034 to 2035
- ZavzpretZavegepant HydrochlorideJune 2034
- PrepopikCitric Acid, Magnesium Oxide, and Sodium PicosulfateTBD no date yet
About Nurtec ODT
- Generic name rimegepant sulfate
- How it is taken By mouth
- Company Pfizer Inc
- Patent challenges Since February 2024 (FDA)
- More drugs Brand-name drugs starting with N
- Have a question? A pharmacist answers, free. Ask about Nurtec ODT
Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, FDA Paragraph IV Patent Certifications list, NADAC (CMS), CMS Medicare Part D Spending by Drug, Medicaid State Drug Utilization Data, FDA, Generic Competition and Drug Prices (2019). Updated October 9, 2026. Information, not medical advice.